Cart
sales@molnova.com
Home - Products - Others - Other Targets - MIF-IN-2

MIF-IN-2

CAS No. 2756410-57-6

MIF-IN-2( —— )

Catalog No. M35478 CAS No. 2756410-57-6

MIF-IN-2 is a heterocyclic macrophage migration inhibitory factor (MIF) inhibitor with anticancer activity for the study of cancer and autoimmune disorders.CAS 13460-73-86-5

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 411 In Stock
10MG 562 In Stock
25MG 866 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    MIF-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    MIF-IN-2 is a heterocyclic macrophage migration inhibitory factor (MIF) inhibitor with anticancer activity for the study of cancer and autoimmune disorders.CAS 13460-73-86-5
  • Description
    MIF-IN-2 is a migration inhibitory factor (MIF) inhibitor extracted from patent WO2021258272A1 compound 1. MIF-IN-2 can be used for the research of immune inflammation-related diseases.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2756410-57-6
  • Formula Weight
    319.7
  • Molecular Formula
    C14H10ClN3O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC1=NN=C(O1)C=2OC=CC2)C3=CC=C(OC)C=C3Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. FAN G, et, al. Compounds and their uses as mif inhibitors. WO2021258272A1.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • 6-Methoxywogonin

    6-Methoxywogonin shows weak anti-inflammatory effect.

  • Examorelin

    Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?

  • PRRS-PQGAB-C

    PRRS-PQGAB-C

Sign In Join Free